1 (Image 1)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 85534-0017
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 85534-0017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hawaii Repack, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure6 (Image 10)
This text provides information about different doses of a medication called Duloretine (120mg, 60mg, and 20mg) along with a placebo, given once daily. The text also includes a chart showing the percentage of patients improved based on the dosage, with data points representing the percent improvement in pain from baseline. This data could be useful for evaluating the effectiveness of Duloretine at different dosages for pain management.*
Figure 7 (Image 11)
This is a chart comparing the percentage of patients improved in pain after taking Duloretine Delayed-Release 60mg Once Daily (b) versus Placebo. The graph shows percentages from 0 to 100, indicating the level of improvement in pain reported by patients.*
Figure8 (Image 12)
This text provides information on the percentage of patients who improved while taking a Placebo compared to Duloxetine Delayed-Release at 60 mg or 120 mg once daily. The data includes the percentage of improvement in pain from baseline for each group.*
Figure9 (Image 13)
This text provides information on the percentage of patients who experienced improvement in pain levels after taking either a placebo or duloxetine delayed-release at a dose of 60 mg once daily. The data is presented in a format showing the baseline pain levels and the corresponding percentage of improvement.*
Figure10 (Image 14)
This text provides data on the improvement in pain percentage among patients receiving different treatments, including placebo and Duloxetine Delayed-Release at doses of 60/120 mg once daily. The numbers indicate the percentage of improvement in pain from the baseline. The graph displays the changes in pain improvement over time.*
1 (Image 15)
1 (Image 16)
1 (Image 17)
1 (Image 2)
1 (Image 3)
1 (Image 4)
Figure1 (Image 5)
Figure2 (Image 6)
The text provides information on the proportion of patients with relapse over time for two treatments: Placebo and Duloxetine Delayed-Release Capsules. It includes a graph with the time from randomization to relapse in days. The data seems to have been analyzed using the Kaplan-Meier estimator method.*
Figure3 (Image 7)
Figure4 (Image 8)
This text provides data on the percentage of patients who showed improvement in pain after treatment with two different doses of Duloxetine and with a placebo. The percentages are not visible in the provided text.*
Figure5 (Image 9)
This is a chart displaying the percentage of patients improved in terms of pain when taking Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo. The chart shows the percent improvement in pain from baseline for different time points ranging from 220 to 290.*
20 (Label 20mg)
30 (Label 30mg)
60 (Label 60mg)
This text appears to be a list of pharmaceutical products, specifically related to Duloxetine DR Capsules in various dosages and quantities. The text includes details such as NDC numbers, quantities available, manufacturers, and recommended storage conditions. The products mentioned range from 60mg to 80mg capsules in different quantities. The information seems to be related to substitution, manufacturing, and storage guidelines for these pharmaceutical products.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
